发明名称 USE OF PEMIROLAST
摘要 According to the invention there is provided a method for the treatment of airway hyperresponsiveness, which method comprises the administration of pemirolast, or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment. Suitable lower doses of pemirolast are least about 110 mg per day.
申请公布号 US2017112837(A1) 申请公布日期 2017.04.27
申请号 US201615136519 申请日期 2016.04.22
申请人 RSPR Pharma AB 发明人 RAUD Johan;DALSGAARD Carl-Johan;TORNLING Goran
分类号 A61K31/519;A61K45/06 主分类号 A61K31/519
代理机构 代理人
主权项 1. A method for the treatment of airway hyperresponsiveness in a paediatric patient, which method comprises administering pemirolast, or a pharmaceutically acceptable salt thereof, to a human patient of an age that is up to about 24 months and having a condition characterized by airway hyperresponsiveness, wherein said administering is carried out by orally administering a dose effective to reduce airway hyperresponsiveness, which dose is at least about 25 mg per day.
地址 Stockholm SE